Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed director
CC transcript
Inv. presentation
Acq. announced
Appointed CFO
|
|
Innoviva, Inc. (INVA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/28/2020 |
GN
| Entasis Therapeutics Announces $25 Million Private Placement |
| 06/11/2020 |
GN
| Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva |
| 05/07/2020 |
GN
| Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update |
| 04/22/2020 |
GN
| Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva |
| 11/06/2018 |
GN
| Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 08/28/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Allscripts Healthcare Solutions, Dean Foods, Alder BioPharmaceuticals, Innoviva, Chegg, and TEGNA — New Horizons, Emerging Trends, and Upcoming Developments |
| 05/08/2018 |
GN
| Research Report Identifies ILG, Innoviva, iRobot, KBR, KapStone Paper and Packaging, and Lumentum with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 03/06/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Okta, Conduent, Innoviva, PRA Health Sciences, DDR, and Tenet Healthcare — New Horizons, Emerging Trends, and Upcoming Developments |
| 11/09/2017 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth |
| 10/02/2012 |
GN
| Theravance and Alfa Wassermann Enter Into Agreement to Develop and Commercialize Velusetrag for Gastroparesis |
| 09/26/2012 |
GN
| GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application (NDA) Submission in the US for COPD |
| 08/24/2012 |
GN
| GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD |
| 07/17/2012 |
GN
| Theravance to Report Second Quarter 2012 Financial Results on July 31, 2012 |
| 07/10/2012 |
GN
| Theravance Announces Positive Topline Results From TD-1211 Phase 2b Study 0084 for the Treatment of Opioid-Induced Constipation |
| 07/02/2012 |
GN
| GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD |
| 05/16/2012 |
GN
| GlaxoSmithKline Completes Transaction to Increase Its Ownership in Theravance |
| 04/24/2012 |
GN
| Theravance to Present at Investor Conferences in May 2012 |
| 04/12/2012 |
GN
| Theravance to Report First Quarter 2012 Financial Results on April 26, 2012 |
| 03/23/2012 |
GN
| GSK and Theravance Announce Completion of the Relovair(TM)* Registrational Programme and Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD |
| 02/22/2012 |
GN
| Theravance to Present at the Cowen and Company 32nd Annual Health Care Conference |
|
|